A cross-trial comparison of single-agent ibrutinib

Tedeschi, A; Greil, R; Demirkan, F; Robak, T; Moreno, C; Barr, PM; Anz, B; Simpson, D; Gaidano, G; Bairey, O; Stevens, D; Gill, D; Flinn, IW; Kipps, TJ; Burger, JA; Lin, J; Webb, T; Fedorov, V; Styles, L; Gribben, JG; Haematologica. 2020; 105(4):e164-e168

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.

Rinnerthaler, G; Gampenrieder, SP; Hackl, H; Steiner, M; Monzo-Fuentes, C; Melchardt, T; Magnes, T; Huemer, F; Westphal, T; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R; J Clin Med. 2020; 9(6):

Correction to: The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study.

Bjelic-Radisic, V; Fitzal, F; Knauer, M; Steger, G; Egle, D; Greil, R; Schrenk, P; Balic, M; Singer, C; Exner, R; Soelkner, L; Gnant, M BMC CANCER. 2020; 20(1): 87

Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.

Fastner, G; Sedlmayer, F; Widder, J; Metz, M; Geinitz, H; Kapp, K; Fesl, C; Sölkner, L; Greil, R; Jakesz, R; Kwasny, W; Heck, D; Bjelic-Radisic, V; Balic, M; Stöger, H; Wieder, U; Zwrtek, R; Semmler, D; Horvath, W; Melbinger-Zeinitzer, E; Wiesholzer, M; Wette, V; Gnant, M; Eur J Cancer. 2020; 127: 1-20.

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy.

Huemer, F; Piringer, G; Schlintl, V; Hackl, H; Rinnerthaler, G; Thaler, J; Greil, R; Weiss, L; Cancers (Basel). 2020; 12(10):

A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study.

Petzer, AL; Sperr, WR; Buxhofer-Ausch, V; Sliwa, T; Schmidt, S; Greil, R; Wölfler, A; Pichler, P; Dormann, C; Burgstaller, S; Tinchon, C; Lang, A; Goebel, F; Uthman, S; Muenchmeier, N; Valent, P; Wien Klin Wochenschr. 2020; 132(15-16):415-422

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.

Steger, GG; Egle, D; Bartsch, R; Pfeiler, G; Petru, E; Greil, R; Helfgott, R; Marth, C; Öhler, L; Hubalek, M; Lang, A; Tinchon, C; Haslbauer, F; Redl, A; Hock, K; Hennebelle, M; Mraz, B; Gnant, M; Breast. 2020; 50:64-70

Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial.

Bjelic-Radisic, V; Fitzal, F; Knauer, M; Steger, G; Egle, D; Greil, R; Schrenk, P; Balic, M; Singer, C; Exner, R; Soelkner, L; Gnant, M; BMC Cancer. 2020; 20(1):392

Safe application of extensive radiotherapy to a cardiac resynchronization device.

Schernthaner, C; Kopp, M; Dagn, K; Rettenbacher, L; Weiss, L; Meyersburg, D; Brandt, MC; Hoppe, UC; Strohmer, B; ESC Heart Fail. 2020; 7(6):4293-4296

Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy.

Schaffler-Schaden, D; Sassmann, R; Johansson, T; Gampenrieder, SP; Rinnerthaler, G; Lampl, K; Herfert, J; Lenzhofer, C; Landkammer, YT; Rieder, F; Greil, R; Flamm, M; Niebauer, J; Medicine (Baltimore). 2020; 99(19): e20149